Home/Pipeline/ACTM-838

ACTM-838

Advanced Solid Tumors

Phase 1a/1bActive

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1a/1b

Status

Active

Company

Actym Therapeutics

About Actym Therapeutics

Actym Therapeutics is a private, clinical-stage biotech developing the STACT™ platform, a systemically administered, engineered bacterial delivery system designed to localize in tumors and produce immunotherapies on-site to avoid systemic toxicity. The company's lead candidate, ACTM-838, is in Phase 1 trials for solid tumors, targeting a major unmet need in immuno-oncology. Backed by notable venture capital investors and led by a team with deep expertise, Actym aims to overcome tumor resistance by harnessing the innate intelligence of bacteria to create potent and localized immune responses.

View full company profile

Therapeutic Areas

Oncology Fibrotic Diseases

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active